4530 — Hisamitsu Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00- ¥425bn
- ¥312bn
- ¥163bn
Table: Hisamitsu -2020/21 parent results
Table: Hisamitsu -2020/21 group forecast
Table: Hisamitsu - 9-MTH group results
Table: Hisamitsu - 6-MTH group results
Table: Hisamitsu -Q1 group results
Table: Hisamitsu -2019/20 group results
Table: Hisamitsu -2019/20 parent results
Table: Hisamitsu - 9-MTH group results
Brief: U.S. FDA Approves SECUADO Transdermal System, The First-And-Only Transdermal Patch For The Treatment Of Adults With Schizophrenia
Table: Hisamitsu - 6-MTH group results
Table: Hisamitsu -Q1 group results
Table: Hisamitsu -2018/19 group results
Table: Hisamitsu -2018/19 parent results
Brief: Hisamitsu Pharmaceutical Signs Agreement With Kyowa Hakko Kirin For Parkinson's Disease Treatment Hisamitsu Is Developing
Table: Hisamitsu - 9-MTH group results
Table: Hisamitsu - 6-MTH group results
Brief: Hisamitsu Pharmaceutical Expected To Post 15 PCt Drop In H1 Operating Profit To 11 BLn Yen - Nikkei
Table: Hisamitsu -Q1 group results
Brief: Hisamitsu Pharmaceutical Co's Operating Profit For March-May Qtr Likely Slid 12 Pct - Nikkei